What Is New in the Treatment of Steroid-Induced Osteoporosis?

Seminars in Cutaneous Medicine and Surgery

Volumn 25, Issue 2, 2006, Pages 72-78

  Liu, Rosemarie H ^a   Werth, Victoria P ^b  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bisphosphonates; calcitonin; calcium; glucocorticoids; osteoporosis; parathyroid hormone; treatment; vitamin D

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; ERGOCALCIFEROL; ESTROGEN; ETIDRONIC ACID; FLUORIDE; FORTICAL; GESTAGEN; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; VITAMIN D; VITAMIN D DERIVATIVE; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DENSITY; BONE NECROSIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; FETUS DISEASE; FEVER; FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOGONADISM; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; RHINITIS; RISK ASSESSMENT; SKELETON MALFORMATION; TOOTH INFECTION;

DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 33746899316     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2006.04.003     Document Type: Review

References (65)

1. Van Staa T.P., Leufkens H.G., and Cooper C. The epidemiology of corticosteroid-induced osteoporosis. a meta-analysis. Osteoporos Int 13 (2002) 777-787
2. Baxter J.D. Advances in glucocorticoid therapy. Adv Intern Med 45 (2000) 317-349
3. Van Staa T.P., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15 (2000) 993-1000
4. Ton F.N., Gunawardene S.C., Lee H., et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20 (2005) 464-470
5. Reid I.R. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 14 (2000) 279-298
6. Lukert B., and Kream B. Clinical and basic aspects of glucocorticoid action in bone. In: Bilezikian J.P., Raisz LG, and Rodan G.A. (Eds). Principles of bone biology (1996), Academic Press, San Diego, CA 533-548
7. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 15 (2003) 454-457
8. Rehman Q., and Lane N.E. Effect of glucocorticoids on bone density. Med Pediatr Oncol 41 (2003) 212-216
9. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44 (2001) 1496-1503
10. Sambrook P., Birmingham J., Kelly P., et al. Prevention of corticosteroid osteoporosis. a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328 (1993) 1747-1752
11. Buckley L.M., Leib E.S., Cartularo K.S., et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. a randomized, double-blind, placebo controlled trial. Ann Intern Med 125 (1996) 961-968
12. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339 (1998) 292-299
13. Porthouse J., Cockayne S., King C., et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 330 7498 (2005) 1003
14. Gilman A.G., Hardman J.G., and Limbird L.E. Goodman & Gilman's The Pharmacological Basis of Therapeutics. ed 10 (2001), McGraw-Hill, New York
15. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 65 (1999) 317-327
16. Richy F., Schacht E., Bruyere O., et al. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures. a comparative meta-analysis. Calcif Tissue Int 76 (2005) 176-186
17. de Nijs R.N., Jacobs J.W., Algra A., et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues. a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15 (2004) 589-602
18. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
19. Taranta A., Brama M., Teti A., et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 (2002) 368-376
20. Reid I.R., Wattie D.J., Evans M.C., et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156 (1996) 1173-1177
21. Crawford B.A., Liu P.Y., Kean M.T., et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88 (2003) 3167-3176
22. Azria M. The Calcitonins. Physiology and Pharmacology (1989), Karger, Basel
23. Chambers T.J., and Magnus C.J. Calcitonin alters behaviour of isolated osteoclasts. J Pathol 136 (1982) 27-39
24. Cranney A., Welch V., Adachi J.D., et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2 (2000) CD001983
25. Tascioglu F., Colak O., Armagan O., et al. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids. a comparison of alendronate and intranasal salmon calcitonin. Rheumatol Int (2005)
26. Silverman S.L., and Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13 (2002) 858-867
27. Knopp J.A., Diner B.M., Blitz M., et al. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures. a systematic review of randomized, controlled trials. Osteoporos Int 16 (2005) 1281-1290
28. Silverman S.L. Calcitonin. Endocrinol Metab Clin N Am 32 (2003) 273-284
29. Ikegame M., Ejiri S., and Ozawa H. Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors. Bone 35 (2004) 27-33
30. Chesnut C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 109 (2000) 267-276
31. Fosamax. http://www.pdr.net/druginformation/DocumentSearch.aspx?documentId=52401893&drugname=Fosamax%20Oral%20Solution. Accessed June 3, 2006
32. Lin J.H. Bisphosphonates. a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
33. Nancollas G.H., Mangood A.H., Gaafar E.M., et al. Mineral binding affinities of bisphosphonates. Bone 30 suppl (2002) 42S, B22 (abstr)
34. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 (1995) 1437-1443
35. Pols H.A., Felsenberg D., Hanley D.A., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9 (1999) 461-468
36. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss. a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42 (1999) 2309-2318
37. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res 15 (2000) 1006-1013
38. Reid D.M., Adami S., Devogelaer J.P., et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69 (2001) 242-247
39. Sato S., Ohosone Y., Suwa A., et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease. 3 year followup. J Rheumatol 30 (2003) 2673-2679
40. Struijs A., Smals A., de Witte S.A., et al. Acute effects of etidronate on glucocorticoid-induced bone degradation. Rheumatology 39 (2000) 523-529
41. Campbell I.A., Douglas J.G., Francis R.M., et al. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 59 (2004) 761-768
42. Adachi J.D., Roux C., Pitt P.I., et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 27 (2000) 2424-2431
43. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337 (1997) 382-387
44. Geusens P., Dequeker J., Vanhoof J., et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis 57 (1998) 724-727
45. Boutsen Y., Jamart J., Esselinckx W., et al. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium. a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16 (2001) 104-112
46. Ringe J.D., Dorst A., Faber H., et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis. results from a long-term comparative study. Osteoporos Int 14 (2003) 801-807
47. Souza S.C., Borges C.T., Jorgetti V., et al. The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus. Rev Hosp Clin Fac Med Sao Paulo 59 (2004) 302-305
48. Amin S., LaValley M.P., Simms R.W., et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis. a meta-regression. J Bone Miner Res 17 (2002) 1512-1526
49. Saag K.G. Prevention of glucocorticoid-induced osteoporosis. South Med J 97 (2004) 555-558
50. Actonel. http://www.pdr.net/druginformation/DocumentSearch.aspx?documentId=65450100&drugname=Actonel%20Tablets. Accessed June 3, 2006
51. Franchimont N., and Canalis E. Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmunity Rev 2 (2003) 224-228
52. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
53. Woo S.B., Hande K., and Richardson P.G. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
54. Liu R.H., Albrecht J., and Werth V.P. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroids. Arch Dermatol 142 (2006) 37-41
55. Aagaard E.M., Lin P., Modin G.W., et al. Prevention of glucocorticoid-induced osteoporosis. provider practice at an urban county hospital. Am J Med 107 (1999) 456-460
56. Hart S.R., and Green B. Osteoporosis prophylaxis during corticosteroid treatment. failure to prescribe. Postgrad Med J 78 (2002) 242-243
57. Quattrocchi E., and Kourlas H. Teriparatide. a review. Clin Ther 26 (2004) 841-854
58. Lane N.E., Sanchez S., Modin G.W., et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. results of a randomized controlled clinical trial. J Clin Invest 102 (1998) 1627-1633
59. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
60. Vahle J.L., Sato M., Long G.G., et al. Skeletal changes in rates given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for two years and relevance to human safety. Toxicol Pathol 30 (2002) 312-321
61. Hodsman A.B., Bauer D.C., Dempster D.W., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis. a review of the evidence and suggested guidelines for its use. Endocr Rev 26 (2005) 688-703
62. Forteo (teriparatide [rDNA origin] injection) [package insert]. Product Information (2002), Eli Lilly and Co, Indianapolis, IN
63. Kurland E.S., Heller S.L., Diamond B., et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int 15 (2004) 992-997
64. Cohen D., and Adachi J.D. The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 88 (2004) 337-349
65. Curtis J.R., Westfall A.O., Allison J.J., et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52 (2005) 2485-2494